Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2013 Feb 11;210(2):209-23.
doi: 10.1084/jem.20121827.

Neutralizing antibodies to HIV-1 induced by immunization

Laura E McCoy  1 , Robin A Weiss
Affiliations
Review

Neutralizing antibodies to HIV-1 induced by immunization

Laura E McCoy et al. J Exp Med. .

Abstract

Most neutralizing antibodies act at the earliest steps of viral infection and block interaction of the virus with cellular receptors to prevent entry into host cells. The inability to induce neutralizing antibodies to HIV has been a major obstacle to HIV vaccine research since the early days of the epidemic. However, in the past three years, the definition of a neutralizing antibody against HIV has been revolutionized by the isolation of extremely broad and potent neutralizing antibodies from HIV-infected individuals. Considerable hurdles remain for inducing neutralizing antibodies to a protective level after immunization. Meanwhile, novel technologies to bypass the induction of antibodies are being explored to provide prophylactic antibody-based interventions. This review addresses the challenge of inducing HIV neutralizing antibodies upon immunization and considers notable recent advances in the field. A greater understanding of the successes and failures for inducing a neutralizing response upon immunization is required to accelerate the development of an effective HIV vaccine.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Neutralizing mAbs targeting HIV Env. The diagram was adapted from Burton and Weiss (2010).
See this image and copyright information in PMC

References

    1. Abdool Karim Q., Abdool Karim S.S., Frohlich J.A., Grobler A.C., Baxter C., Mansoor L.E., Kharsany A.B., Sibeko S., Mlisana K.P., Omar Z., et al. ; CAPRISA 004 Trial Group 2010. Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science. 329:1168–1174 10.1126/science.1193748 - DOI - PMC - PubMed
    1. Ahmed F.K., Clark B.E., Burton D.R., Pantophlet R. 2012. An engineered mutant of HIV-1 gp120 formulated with adjuvant Quil A promotes elicitation of antibody responses overlapping the CD4-binding site. Vaccine. 30:922–930 10.1016/j.vaccine.2011.11.089 - DOI - PMC - PubMed
    1. Alam S.M., Morelli M., Dennison S.M., Liao H.X., Zhang R., Xia S.M., Rits-Volloch S., Sun L., Harrison S.C., Haynes B.F., Chen B. 2009. Role of HIV membrane in neutralization by two broadly neutralizing antibodies. Proc. Natl. Acad. Sci. USA. 106:20234–20239 10.1073/pnas.0908713106 - DOI - PMC - PubMed
    1. Andrus L., Prince A.M., Bernal I., McCormack P., Lee D.H., Gorny M.K., Zolla-Pazner S. 1998. Passive immunization with a human immunodeficiency virus type 1-neutralizing monoclonal antibody in Hu-PBL-SCID mice: isolation of a neutralization escape variant. J. Infect. Dis. 177:889–897 10.1086/515251 - DOI - PubMed
    1. Arnold G.F., Velasco P.K., Holmes A.K., Wrin T., Geisler S.C., Phung P., Tian Y., Resnick D.A., Ma X., Mariano T.M., et al. 2009. Broad neutralization of human immunodeficiency virus type 1 (HIV-1) elicited from human rhinoviruses that display the HIV-1 gp41 ELDKWA epitope. J. Virol. 83:5087–5100 10.1128/JVI.00184-09 - DOI - PMC - PubMed

MeSH terms